Stereoselective inhibition of the hERG1 potassium channel

A growing number of drugs have been shown to prolong cardiac repolarization, predisposing individuals to life-threatening ventricular arrhythmias known as Torsades de Pointes. Most of these drugs are known to interfere with the human ether à-gogo related gene 1 (hERG1) channel, whose curren...

Full description

Bibliographic Details
Main Authors: Liliana eSintra Grilo, Pierre-Alain eCarrupt, Hugues eAbriel
Format: Article
Language:English
Published: Frontiers Media S.A. 2010-11-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fphar.2010.00137/full
id doaj-eea6bcfafd964aa79a3ea5c8c4453755
record_format Article
spelling doaj-eea6bcfafd964aa79a3ea5c8c44537552020-11-24T23:02:29ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122010-11-01110.3389/fphar.2010.001377878Stereoselective inhibition of the hERG1 potassium channelLiliana eSintra Grilo0Liliana eSintra Grilo1Pierre-Alain eCarrupt2Hugues eAbriel3University of BernUniversity of GenevaUniversity of GenevaUniversity of BernA growing number of drugs have been shown to prolong cardiac repolarization, predisposing individuals to life-threatening ventricular arrhythmias known as Torsades de Pointes. Most of these drugs are known to interfere with the human ether à-gogo related gene 1 (hERG1) channel, whose current is one of the main determinants of action potential duration. Prolonged repolarization is reflected by lengthening of the QT interval of the electrocardiogram, as seen in the suitably named drug-induced long QT syndrome. Chirality (presence of an asymmetric atom) is a common feature of marketed drugs, which can therefore exist in at least two enantiomers with distinct three-dimensional structures and possibly distinct biological fates. Both the pharmacokinetic and pharmacodynamic properties can differ between enantiomers, as well as also between individuals who take the drug due to metabolic polymorphisms. Despite the large number of reports about drugs reducing the hERG1 current, potential stereoselective contributions have only been scarcely investigated. In this review, we present a non-exhaustive list of clinically important molecules which display chiral toxicity that may be related to hERG1-blocking properties. We particularly focus on methadone cardiotoxicity, which illustrates the importance of the stereoselective effect of drug chirality as well as individual variations resulting from pharmacogenetics. Furthermore, it seems likely that, during drug development, consideration of chirality in lead optimization and systematic assessment of the hERG1 current block with all enantiomers could contribute to the reduction of the risk of drug-induced LQTS.http://journal.frontiersin.org/Journal/10.3389/fphar.2010.00137/fullLong QT Syndromeenantiomercardiotoxicitycardiac channelopathieshERG1voltage-gated potassium channel
collection DOAJ
language English
format Article
sources DOAJ
author Liliana eSintra Grilo
Liliana eSintra Grilo
Pierre-Alain eCarrupt
Hugues eAbriel
spellingShingle Liliana eSintra Grilo
Liliana eSintra Grilo
Pierre-Alain eCarrupt
Hugues eAbriel
Stereoselective inhibition of the hERG1 potassium channel
Frontiers in Pharmacology
Long QT Syndrome
enantiomer
cardiotoxicity
cardiac channelopathies
hERG1
voltage-gated potassium channel
author_facet Liliana eSintra Grilo
Liliana eSintra Grilo
Pierre-Alain eCarrupt
Hugues eAbriel
author_sort Liliana eSintra Grilo
title Stereoselective inhibition of the hERG1 potassium channel
title_short Stereoselective inhibition of the hERG1 potassium channel
title_full Stereoselective inhibition of the hERG1 potassium channel
title_fullStr Stereoselective inhibition of the hERG1 potassium channel
title_full_unstemmed Stereoselective inhibition of the hERG1 potassium channel
title_sort stereoselective inhibition of the herg1 potassium channel
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2010-11-01
description A growing number of drugs have been shown to prolong cardiac repolarization, predisposing individuals to life-threatening ventricular arrhythmias known as Torsades de Pointes. Most of these drugs are known to interfere with the human ether à-gogo related gene 1 (hERG1) channel, whose current is one of the main determinants of action potential duration. Prolonged repolarization is reflected by lengthening of the QT interval of the electrocardiogram, as seen in the suitably named drug-induced long QT syndrome. Chirality (presence of an asymmetric atom) is a common feature of marketed drugs, which can therefore exist in at least two enantiomers with distinct three-dimensional structures and possibly distinct biological fates. Both the pharmacokinetic and pharmacodynamic properties can differ between enantiomers, as well as also between individuals who take the drug due to metabolic polymorphisms. Despite the large number of reports about drugs reducing the hERG1 current, potential stereoselective contributions have only been scarcely investigated. In this review, we present a non-exhaustive list of clinically important molecules which display chiral toxicity that may be related to hERG1-blocking properties. We particularly focus on methadone cardiotoxicity, which illustrates the importance of the stereoselective effect of drug chirality as well as individual variations resulting from pharmacogenetics. Furthermore, it seems likely that, during drug development, consideration of chirality in lead optimization and systematic assessment of the hERG1 current block with all enantiomers could contribute to the reduction of the risk of drug-induced LQTS.
topic Long QT Syndrome
enantiomer
cardiotoxicity
cardiac channelopathies
hERG1
voltage-gated potassium channel
url http://journal.frontiersin.org/Journal/10.3389/fphar.2010.00137/full
work_keys_str_mv AT lilianaesintragrilo stereoselectiveinhibitionoftheherg1potassiumchannel
AT lilianaesintragrilo stereoselectiveinhibitionoftheherg1potassiumchannel
AT pierrealainecarrupt stereoselectiveinhibitionoftheherg1potassiumchannel
AT hugueseabriel stereoselectiveinhibitionoftheherg1potassiumchannel
_version_ 1725636537438175232